Role of Oxytocin in Telling and Detecting Lies

The University of Texas System (UT)

Status and phase: Withdrawn; Early Phase 1

Conditions: Dyssocial Behavior

Treatments: Drug: Oxytocin

Study type: Interventional

Funder types: Other

Identifiers

NCT02361177

2013-11-0033

Details and patient eligibility

About

The investigators are interested in the impact of intranasal oxytocin in unethical behavior.

Full description

The objective of this project is to further explore the role of oxytocin in moral judgment and ethical behavior. Oxytocin is a peptide hormone produced in a variety of hypothalamic neurons. It is released into the brain or brought into general circulation through sensory stimuli in a pulsatile fashion. In social psychology research, oxytocin is hypothesized to coordinate both the causes and effects of positive social interactions in a biofeedback loop.

Sex: Male

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male

Exclusion criteria

• _____ _____BP > 130/85, HRT > 95 (can be included at discretion of study physician/designee)

  • _____History of seizures
  • _____Neurological Disorder
  • _____Current psychiatric disorder
  • _____Previous psychiatric disorder (can be included at discretion of PI)
  • Date last episode (if > 1 year, include; if <1 year, at discretion of PI)
  • _____Current use of psychoactive drugs
  • Previous use of psychoactive drugs (can be included at discretion of PI) Date last medicated Type of medication_________________________
  • _____Current use of anticoagulants
  • _____Current use of corticosteroids
  • _____Previous head trauma (can be included at discretion of PI)
  • _____Alcoholism or substance abuse
  • _____Carcinoma of the breast or prostate
  • _____Renal or Hepatic diseases
  • _____Chronic lung diseases
  • _____Cancer
  • _____Liver problems
  • _____Hypertension/Cardiac diseases
  • _____Cardiovascular Disease
  • _____Nephritis
  • _____Diabetes (use of insulin) /Obesity
  • _____Endocrine disease or malignancy
  • _____Asthma (can be included as discretion of study physician/designee, if episodes are infrequent, nonmedicated, and no active problems at time of study)
  • Medication
  • Frequency of episodes____ Date of last episode
  • _____Migraines(can be included as discretion of study physician/designee, if episodes are infrequent, nonmedicated, and no active problems at time of study)
  • Medication Frequency of migraines Date of last migraine
  • _____High levels of physical contact with women or children

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

oxytocin

Experimental group

Description:

Intranasal 24 IU oxytocin self-administration.

Treatment:

Drug: Oxytocin

placebo

Placebo Comparator group

Description:

Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.

Treatment:

Drug: Oxytocin